Find Ophthalmology Drugs in Phase I/II Clinical Development in GERMANY

Lead Product(s): EYS606

Therapeutic Area: Ophthalmology

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Boehringer Ingelheim Venture Fund

Deal Size: $30.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing January 08, 2020

Details:

The company will use the funds to continue the development of its clinical lead candidate EYS606 for the treatment of chronic non-infectious uveitis (NIU), including the launch of its Electro Study.